Eli Lilly market share slips in India as cheap semaglutide surges

The Indian GLP‑1 market is shifting rapidly as a wave of low‑cost semaglutide generics enter following patent expiries, denting Eli Lilly’s early lead with its tirzepatide product Mounjaro. Market trackers reported a notable rise in semaglutide's share alongside a decline in Mounjaro's relative value share.

The acceleration followed the expiry of semaglutide protection in India in March 2026, prompting multiple domestic manufacturers to launch generic versions within weeks. Data show semaglutide's volume share rising month‑on‑month while branded competitors face price pressure; industry commentary suggests initial generic pricing could be substantially lower than originator levels, reshaping prescribing and access dynamics.

The immediate market impact has been on pricing power and sales mix. Novo Nordisk implemented substantial price reductions for Wegovy and Ozempic in India to broaden access and defend market presence, a move analysts view as tactical defense against low‑cost entrants. Branded high‑price GLP‑1s are seeing slower value growth even as total treatment volumes expand.

In a broader context, this Indian episode is an early indicator of how semaglutide losing exclusivity could play out globally: greater volume penetration at much lower price points, shifting revenue profiles for originators, and potential margin compression across the class. Stakeholders from multinational pharma to local generics makers are recalibrating strategies around distribution partnerships and value‑for‑money positioning.

Looking ahead, analysts expect branded players to respond with a mix of price adjustments, patient assistance programs and commercial alliances to protect share, while generics are likely to capture significant volume quickly in price‑sensitive markets. Key metrics for investors and market participants will be month‑on‑month volume trends, average selling price movements and the pace of new generic launches. The competitive dynamics in India may presage similar pressure in other emerging markets as patents expire.